



EUROPEAN COMMISSION  
DG ENVIRONMENT

## **GRANT AGREEMENT**

**LIFE13 ENV/IT/000482**

**Phthalates and bisphenol A biomonitoring  
in Italian mother-child pairs: link between  
exposure and juvenile diseases**



EUROPEAN COMMISSION  
DIRECTORATE-GENERAL  
ENVIRONMENT  
Directorate E – Global & Regional Challenges, LIFE  
ENV.E.4 – LIFE Environment

## GRANT AGREEMENT

AGREEMENT NUMBER LIFE13 ENV/IT/000482

The European Union (“the Union”), represented by the European Commission (“the Commission”), itself represented for the purposes of signature of this agreement by Mr. Hervé MARTIN, Head of Unit, DG Environment,

of the one part,

and

Istituto Superiore di Sanità  
Viale Regina Elena, 299  
00161 Rome  
Italy

(“the coordinating beneficiary”), represented for the purposes of signature of this agreement by Mr. Fabrizio OLEARI, Director,

and the following “associated beneficiaries” :

National Research Council - Institute of Clinical Physiology, (IFC-CNR), Pisa, Italy  
Piazzale A. Moro, 7  
00185 Roma  
Italy

Bambino Gesù Children's Hospital  
Piazza S. Onofrio, 4  
00165 Rome  
Italy

duly represented by the coordinating beneficiary by virtue of the mandate, included in Annex I – Form A4, for the signature of this agreement

of the other part,

hereinafter referred to collectively as "the beneficiaries", and individually as "beneficiary" for the purposes of this agreement where a provision applies without distinction between the coordinating beneficiary or an associated beneficiary,

## HAVE AGREED

The **special provisions** and **common provisions** set out below and the following **Annexes**:

- Annex I** Description of the project including estimated budget and mandates provided to the coordinating beneficiary by the associated beneficiaries
- Annex II** Standard statement of expenditure  
<http://ec.europa.eu/environment/life/toolkit/pmttools/lifeplus/reporting.htm>
- Annex III** LIFE logo  
<http://ec.europa.eu/environment/life/toolkit/comtools/resources/logos.htm>
- Annex IV** Standard audit report  
<http://ec.europa.eu/environment/life/toolkit/pmttools/lifeplus/reporting.htm>
- Annex V** Financial identification of the coordinating beneficiary  
[http://ec.europa.eu/budget/contracts\\_grants/info\\_contracts/financial\\_id/financial\\_id\\_en.cfm](http://ec.europa.eu/budget/contracts_grants/info_contracts/financial_id/financial_id_en.cfm)

which form an integral part of this agreement, hereinafter referred to as "the grant agreement".

## SPECIAL PROVISIONS

---

### Article 1

In the framework of Regulation (EC) N° 614/2007 of the European Parliament and of the Council of 23 May 2007 concerning the Financial Instrument for the Environment (LIFE+) the Commission has decided to award a grant under the terms and conditions set out in the Special Provisions, the Common Provisions and the Annexes to the grant agreement, for the project entitled "Phthalates and bisphenol A biomonitoring in Italian mother-child pairs: link between exposure and juvenile diseases" ("the project") as described in Annex I.

With the signature of the grant agreement, the coordinating beneficiary and any associated beneficiary where relevant accept the grant and agree to implement the project, acting on their own responsibility.

Two identical copies of the grant agreement have been produced, each signed by the Commission and the coordinating beneficiary.

### Article 2

The grant agreement shall enter into force on the date when the last of the two parties signs.

The project shall run from 01.09.2014 to 31.03.2018.


The grant shall be of a maximum amount of € 877,658 and shall take the form of reimbursement of 47.06% of the eligible costs actually incurred for the project, which are estimated at € 1,864,888.

The final amount of the grant is determined as defined in Article 23 of the Common Provisions.


### Article 3

Done at Brussels in two copies, on 18 JUL. 2014

For the coordinating beneficiary,

  
Fabrizio OLEARI  
Director

For the Commission,

  
Hervé MARTIN  
Head of Unit



LIFE+ 2013

FOR ADMINISTRATION USE ONLY

LIFE13 ENV/IT/000482

## LIFE+ Environment Policy and Governance project application

### Language of the proposal:

English (en)

### Project title:

Phthalates and bisphenol A biomonitoring in Italian mother-child pairs: link between exposure and juvenile diseases

### Project acronym:

LIFE PERSUADED

### The project will be implemented in the following Member State(s):

Italy All regions

Expected start date: 01/09/2014

Expected end date: 31/03/2018

### LIST OF BENEFICIARIES

Name of the coordinating beneficiary: Istituto Superiore di Sanità

Name of the associated beneficiary: National Research Council - Institute of Clinical Physiology, (IFC-CNR), Pisa, Ita

Name of the associated beneficiary: Bambino Gesù Children's Hospital

### LIST OF CO-FINANCIERS

### PROJECT BUDGET AND REQUESTED EU FUNDING

Total project budget:	1,866,398 Euro	
Total eligible project budget:	1,864,888 Euro	
EU financial contribution requested:	877,658 Euro	(= 47.06% of total eligible budget)

### PROJECT POLICY AREA

Environment and Health

**Coordinating Beneficiary Profile Information**

Legal Name	Istituto Superiore di Sanità		
Short Name	ISS	Legal Status	
VAT No	0365773100	Public body	<input checked="" type="checkbox"/>
Legal Registration No	80211730587	Private commercial	<input type="checkbox"/>
Registration Date	02/08/2001	Private non-commercial	<input type="checkbox"/>

**Legal address of the Coordinating Beneficiary**

Street Name and No	Viale Regina Elena, 299		
Post Code	00161	PO Box	
Town / City	Rome		
Member State	Italy		

**Coordinating Beneficiary contact person information**

Title	N/A	Function	Senior scientist
Surname	La Rocca		
First Name	Cinzia		
E-mail address	cinzia.larocca@iss.it		
Department / Service	Department of Veterinary Public Health and Food Safety		
Street Name and No	Viale Regina Elena, 299		
Post Code	00161	PO Box	
Town / City	Rome		
Member State	Italy		
Telephone No	3949902992	Fax No	

**Website of the Coordinating Beneficiary**

Website	www.iss.it/inte
---------	-----------------

**Brief description of the Coordinating Beneficiary's activities and experience in the area of the proposal**

The Istituto Superiore di Sanità (ISS) is the leading technical and scientific public body of the Italian National Health Service. Its activities include research, control, training and consultation in the interest of public health protection, including scientific advice to Ministry of Health and European Commission. The ISS is the major Italian institution devoted to research in public health. The Institute conducts scientific research in a wide variety of fields, from cutting-edge molecular and genetic research to population-based studies of risk factors for disease and disability. Research priorities are based on those set forth in the National Health Plan.

Main activities of the ISS include chemical and toxicological risk assessment, food safety, environmental and human health. ISS is a scientific consultant at both national and EU level on such topics as REACH, testing and assessment of endocrine disrupting chemicals (EDCs), environment and health as well as new guidelines on toxicological testing; thus, ISS acts as an interface between research and risk assessment, providing scientific consultancy services at national and international levels (e.g. EU/EC, IARC, NATO, OECD, UNEP, WHO) and contributes to national and EU regulatory provisions. ISS is head quarters of National Focal Point of the European Food Safety Authority (EFSA), keystone of EU risk assessment regarding food and feed safety.



### COORDINATING BENEFICIARY DECLARATION

The undersigned hereby certifies that:

1. The specific actions listed in this proposal do not and will not receive aid from the Structural Funds or other European Union financial instruments. In the event that any such funding will be made available after the submission of the proposal or during the implementation of the project, my organisation will immediately inform the European Commission.
2. My organisation Istituto Superiore di Sanità has not been served with bankruptcy orders, nor has it received a formal summons from creditors. My organisation is not in any of the situations listed in Articles 93.1 and 94 of Council Regulation 1605/2002 of 25/06/2002 (OJ L248 of 16/09/2002).
3. My organisation (which is legally registered in the European Union) will contribute 396,951.00€ to the project. My organisation will participate in the implementation of the following actions: A1, A2, A3, B1, B5, B6, B8, C1, D1, D2, D3, D4, D5, D6, D7, D8, E1, E2, E3. The estimated total cost of my organisation's part in the implementation of the project is 757,769.00 €.

Should one or more associated beneficiary or co-financier reduce or withdraw its financial contribution, my organisation will ensure that a corresponding additional contribution is made available.

My organisation will conclude with the associated beneficiaries and co-financiers any agreements necessary for the completion of the work, provided these do not infringe on their obligations, as stated in the grant agreement with the European Commission. Such agreements will be based on the model proposed by the European Commission. They will describe clearly the tasks to be performed by each associated beneficiary and define the financial arrangements.

I am aware that my organisation is solely legally and financially responsible to the Commission for the implementation of the project (Article 4 of the Common Provisions).

I am legally authorised to sign this statement on behalf of my organisation.

I have read in full the Common Provisions (attached to the Model Grant Agreement provided with the LIFE+ application files).

I certify to the best of my knowledge that the statements made in this proposal are true and the information provided is correct.

At Palermo, ..... on 01.06.2016.....

Signature of the Coordinating Beneficiary:

Name(s) and status of signatory: Dr. FABRIZIO CLEARI

N. 0002113

10/03/2014

LIFE13 ENV/ - A4



### ASSOCIATED BENEFICIARY DECLARATION and MANDATE

I, the undersigned, EVANIO PICANO (1), representing, National Research Council - Institute of Clinical Physiology, (IFC-CNR), Pisa, Italy. IFC-CNR, Public body, 80054330586, VAT number IT02118311006, Piazzale A. Moro, n. 7, Roma, 00185, Italy, hereinafter referred to as "the associated beneficiary", for the purposes of the signature and the implementation of the grant agreement Phthalates and bisphenol A biomonitoring in Italian mother-child pairs: link between exposure and juvenile diseases with the European Commission (hereinafter referred to as "the grant agreement") hereby:

1. Mandate Istituto Superiore di Sanità (ISS), Public body, 80211730587, VAT number 0365773100, Viale Regina Elena, 299, Rome, 00161, Italy, represented by ..... (hereinafter referred to as "the coordinating beneficiary") to sign in my name and on my behalf the grant agreement and its possible subsequent amendments with the European Commission.

2. Mandate the coordinating beneficiary to act on behalf of the associated beneficiary in compliance with the grant agreement.

I hereby confirm that the associated beneficiary accepts all terms and conditions of the grant agreement and, in particular, all provisions affecting the coordinating beneficiary and the associated beneficiaries. In particular, I acknowledge that, by virtue of this mandate, the coordinating beneficiary alone is entitled to receive funds from the Commission and distribute the amounts corresponding to the associated beneficiary's participation in the action.

I hereby accept that the associated beneficiary will do everything in its power to help the coordinating beneficiary fulfil its obligations under the grant agreement, and in particular, to provide to the coordinating beneficiary, on its request, whatever documents or information may be required.

I hereby declare that the associated beneficiary agrees that the provisions of the grant agreement, including this mandate, shall take precedence over any other agreement between the associated beneficiary and the coordinating beneficiary which may have an effect on the implementation of the grant agreement.

I furthermore certify that:

- The associated beneficiary has not been served with bankruptcy orders, nor has it received a formal summons from creditors. My organisation is not in any of the situations listed in Articles 106(1) and 107 of Council Regulation No 966/2012 of the European Parliament and of the Council of 25 October 2012 on the financial rules applicable to the general budget of the Union (OJ L298 of 26.10.2012).
- The associated beneficiary (which is legally registered in the European Union) will contribute 286764€ to the project. My organisation will participate in the implementation of the following actions: A2, B1, B4, C1, D6, D7, E1. The estimated total cost of my organisation's part in the implementation of the project is 564721€.
- The associated beneficiary will conclude with the coordinating beneficiary an agreement necessary for the completion of the work, provided this does not infringe on our obligations, as stated in the grant agreement with the European Commission. This agreement will be based on the model proposed by the European Commission. It will describe clearly the tasks to be performed by my organisation and define the financial arrangements.

This declaration and mandate shall be annexed to the grant agreement and shall form an integral part thereof.

I am legally authorised to sign this statement on behalf of my organisation. I have read in full the Common Provisions (attached to the Model Grant Agreement provided with the LIFE+ application files). I certify to the best of my knowledge that the statements made in this proposal are true and the information provided is correct.

At Pisa on 10/03/2014

Signature of the Associated Beneficiary:

Name(s) and status/function of signatory:

*Evano Picano*

Forename and surname of the legal representative of the future associated beneficiary signing this mandate.  
When the form is completed, please print, sign, scan and upload it in eProposal





## ASSOCIATED BENEFICIARY DECLARATION and MANDATE

I, the undersigned, Giuseppe Profiti (1), representing, Bambino Gesù Children's Hospital OPBG, Private non-commercial, N/A, VAT number VAT Exemption, Piazza S. Onofrio, 4, Rome, 00165, Italy, hereinafter referred to as "the associated beneficiary", for the purposes of the signature and the implementation of the grant agreement Phthalates and bisphenol A biomonitoring in Italian mother-child pairs: link between exposure and juvenile diseases with the European Commission (hereinafter referred to as "the grant agreement") hereby:

Mandate Istituto Superiore di Sanita (ISS), Public body, 80211730587, VAT number 0365773100, Viale Regina Elena, 299, Rome, 00161, Italy, represented by Fabrizio Olessi (hereinafter referred to as "the coordinating beneficiary") to sign in my name and on my behalf the grant agreement and its possible subsequent amendments with the European Commission.

2. Mandate the coordinating beneficiary to act on behalf of the associated beneficiary in compliance with the grant agreement.

I hereby confirm that the associated beneficiary accepts all terms and conditions of the grant agreement and, in particular, all provisions affecting the coordinating beneficiary and the associated beneficiaries. In particular, I acknowledge that, by virtue of this mandate, the coordinating beneficiary alone is entitled to receive funds from the Commission and distribute the amounts corresponding to the associated beneficiary's participation in the action.

I hereby accept that the associated beneficiary will do everything in its power to help the coordinating beneficiary fulfil its obligations under the grant agreement, and in particular, to provide to the coordinating beneficiary, on its request, whatever documents or information may be required.

I hereby declare that the associated beneficiary agrees that the provisions of the grant agreement, including this mandate, shall take precedence over any other agreement between the associated beneficiary and the coordinating beneficiary which may have an effect on the implementation of the grant agreement.

I furthermore certify that:

1. The associated beneficiary has not been served with bankruptcy orders, nor has it received a formal summons from creditors. My organisation is not in any of the situations listed in Articles 106(1) and 107 of Council Regulation No 966/2012 of the European Parliament and of the Council of 25 October 2012 on the financial rules applicable to the general budget of the Union (OJ L298 of 26.10.2012).
2. The associated beneficiary (which is legally registered in the European Union) will contribute 305025€ to the project. My organisation will participate in the implementation of the following actions: A3, B1, B2, B3, B7, D6, D7. The estimated total cost of my organisation's part in the implementation of the project is 543908€.
3. The associated beneficiary will conclude with the coordinating beneficiary an agreement necessary for the completion of the work, provided this does not infringe on our obligations, as stated in the grant agreement with the European Commission. This agreement will be based on the model proposed by the European Commission. It will describe clearly the tasks to be performed by my organisation and define the financial arrangements.

This declaration and mandate shall be annexed to the grant agreement and shall form an integral part thereof.

I am legally authorised to sign this statement on behalf of my organisation. I have read in full the Common Provisions (attached to the Model Grant Agreement provided with the LIFE+ application files). I certify to the best of my knowledge that the statements made in this proposal are true and the information provided is correct.

At Rome on 2013/11/27

Signature of the Associated Beneficiary:

Name(s) and status/function of signatory:

Giuseppe Profiti  
President of the Board of Directors

Forename and surname of the

## ASSOCIATED BENEFICIARY PROFILE

## Associated Beneficiary profile information

Legal Name	Bambino Gesù Children's Hospital		
Short Name	OPBG	Legal Status	
VAT No	VAT Exemption	Public body	
Legal Registration No	N/A	Private commercial	
Registration Date	null	Private non-commercial	X

## Legal address of the Coordinating Beneficiary

Street Name and No	Piazza S. Onofrio, 4	PO Box	null
Post Code	00165	Town / City	Rome
Member State	Italy		

## Legal address of the Associated Beneficiary

Website	<a href="http://www.ospedalebambinogesu.it">http://www.ospedalebambinogesu.it</a>
---------	---

## Brief description of the Associated Beneficiary's activities and experience in the area of the proposal

The Bambino Gesù Children Hospital (OPBG) is a Scientific Institute for Research, Hospitalization and Health Care, part of the Italian National Healthcare System, dedicated to paediatric and developing ages, national and international referral centre.

OPBG has over 2500 permanent staff and aprox 180 staff on a non-permanent position. Health care and research are performed across 6 sites, the main one located in Rome. Yearly inpatient activities involve aprox 24000 inpatient admissions and 88000 medical and 5500 surgical day care admissions. Specific research facilities are organized in modern laboratories, fully equipped with high-tech apparatus for molecular, cellular and animal work supporting post-genomics, proteomics, microarray technology, cell and molecular biology, including animal facilities, cores for flow cytometry and cell sorting, TCR spectratyping analyses, sequencing, statistical and informatics analysis. Instrumentation for molecular and cell biology, tissue culture, microscopy, PCR and biosafety level 2 rooms for vector handling. In 2010 OPBG researchers have achieved a total Impact Factor of 1331,15.

Activity in the field of the Project is intense and highly qualified. Among OPBG's 11 Departments, is the Paediatric University-Hospital Department that includes the highly advanced Endocrinology and Molecular Endocrinology Units. In 2010 the Endocrinology U. has treated over 9600 outpatients and over 5000 day care inpatients. Prof. S. Cianfarani, director of the Molecular Endocrinology Unit, also Director of the Paediatric Endocrinology Centre of the Tor Vergata University in Rome, has broad international scientific experience: he worked in an official position in UK (London and Bristol), has published 96 Pubmed peer-reviewed papers, mostly as first or senior Author, in the field of Paediatric Endocrinology, has reviewed over 20 international scientific peer-reviewed Journals, and has been awarded 3 scientific grants by the

## ASSOCIATED BENEFICIARY PROFILE

## Associated Beneficiary profile information

Legal Name	National Research Council - Institute of Clinical Physiology, (IFC-CNR), Pisa, Italy.		
Short Name	IFC-CNR	Legal Status	
AT No	IT02118311006	Public body	<input checked="" type="checkbox"/>
Legal Registration No	80054330586	Private commercial	<input type="checkbox"/>
Registration Date	null	Private non- commercial	<input type="checkbox"/>

## Legal address of the Coordinating Beneficiary

Street Name and No	Piazzale A. Moro, n. 7		PO Box	null
Post Code	00185	Town / City	Roma	
Member State	Italy			

## Legal address of the Associated Beneficiary

Website	<a href="http://www.ifc.cnr.it/">http://www.ifc.cnr.it/</a>
---------	---

## Brief description of the Associated Beneficiary's activities and experience in the area of the proposal

The main interest of the Institute of Clinical Physiology of the National Research Council (IFC-CNR) in Pisa (IFC-CNR) is in the field of cardiovascular and metabolic diseases, which are dealt with through a multi-organ and multisystem prospective, covering associated pathologies of the lungs, kidneys, and the metabolic and neuro-endocrine systems. IFC-CNR hosts laboratories of basic science, biology, biochemistry, molecular medicine, medical statistics, epidemiology, bioengineering, computer science, and experimental medicine. (<http://www.ifc.cnr.it/index.php/en/the-institute>).

Main tasks attributed to the organisation: Set up of web site with implementation of online questionnaire, data store, and monitoring the study. Store and analyses of urine samples; manage the data bank; perform the phthalates and BPA measurements; develop in cooperation with all the other subunit participating to project a risk assessment model.

Budget breakdown cost categories	Total cost in €	Eligible Cost in €	% of total eligible costs
1. Personnel		1,302,483	69.84 %
2. Travel and subsistence		37,000	1.98 %
3. External assistance		119,500	6.41 %
4. Durable goods			
4.a Infrastructure	0	0	0.00 %
4.b Equipment	3,010	1,500	0.08 %
4.c Prototype	0	0	0.00 %
5. Other non-durable goods			
6. Consumables		239,079	12.82 %
7. Other Costs		52,000	2.79 %
8. Overheads		113,326	6.08 %
<b>TOTAL</b>	<b>1,866,398</b>	<b>1,864,888</b>	<b>100 %</b>

Contribution breakdown	In €	% of TOTAL	% of total eligible costs
Requested EU contribution	877,658	47.02 %	47.06 %
Coordinating Beneficiary's contribution	396,951	21.27 %	
Associated Beneficiaries' contribution	591,789	31.71 %	
Co-financiers contribution	0	0.00 %	
<b>TOTAL</b>	<b>1,866,398</b>	<b>100.00 %</b>	

## Coordinating Beneficiary's contribution

Country code	Beneficiary short name	Total costs of the actions in € (including overheads)	Beneficiary's own contribution in €	Amount of EU contribution requested in €
IT	ISS	757,769	396,951	360,818

## Associated Beneficiaries' contribution

Country code	Beneficiary short name	Total costs of the actions in € (including overheads)	Associated beneficiary's own contribution in €	Amount of EU contribution requested in €
IT	IFC-CNR	564,721	286,764	277,957
IT	OPBG	543,908	305,025	238,883
<b>TOTAL Associated Beneficiaries</b>		<b>1,108,629</b>	<b>591,789</b>	<b>516,840</b>
<b>TOTAL All Beneficiaries</b>		<b>1,866,398</b>	<b>988,740</b>	<b>877,658</b>

## Co-financiers contribution

Co-financier's name	Amount of co-financing in €
<b>TOTAL</b>	<b>0</b>